AMR Logo.png
Flow Diverters Market to Hit $1.04 Billion, with CAGR of 15.3% by 2031: Allied Market Research
November 27, 2022 19:00 ET | Allied Market Research
Portland, OR, Nov. 27, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Flow Diverters Market generated $251.50 million in 2021, and is...
InspireMD Logo.png
InspireMD to Present at the H.C. Wainwright 20th Annual Global Investment Conference in New York City
September 04, 2018 07:30 ET | InspireMD, Inc.
TEL AVIV, ISRAEL, Sept. 04, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke...
InspireMD Logo.png
InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering
June 29, 2018 10:24 ET | InspireMD, Inc.
Tel Aviv, Israel, June 29, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD Logo.png
InspireMD’s CGuard™ MicroNet™ EPS Featured in a Live Case Transmission to the 2nd DGA Interventional Congress
June 11, 2018 09:53 ET | InspireMD, Inc.
Tel Aviv, Israel, June 11, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
InspireMD Logo.png
InspireMD Reports on Expanded 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard EPS
May 30, 2018 07:31 ET | InspireMD, Inc.
Results Presented at EuroPCR 2018 Confirm Sustained Safety and Cerebral Embolic Prevention out to 24 months TEL AVIV, ISRAEL, May 30, 2018 (GLOBE NEWSWIRE) --  InspireMD, Inc. (NYSE...
InspireMD Logo.png
InspireMD Reports 132% Increase in CGuard™ EPS Sales for the First Quarter of 2018
May 07, 2018 16:05 ET | InspireMD, Inc.
Tel Aviv, Israel, May 07, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD Logo.png
InspireMD Schedules First Quarter 2018 Earnings Conference Call
May 01, 2018 07:00 ET | InspireMD, Inc.
TEL AVIV, ISRAEL , May 01, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
InspireMD Logo.png
InspireMD Announces Regulatory Approval and Reimbursement to Commercialize both CGuard EPS™ and MGuard™ Prime Products in Vietnam
April 30, 2018 07:34 ET | InspireMD, Inc.
TEL AVIV, ISRAEL, April 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD Logo.png
InspireMD Anticipates Fifth Consecutive Quarter of Sequential Double Digit Growth; Projects 132% Increase in CGuard EPS Sales for the First Quarter of 2018; Total Quarterly Company Sales to Exceed $1 Million
April 03, 2018 10:28 ET | InspireMD, Inc.
TEL AVIV, Israel, April 03, 2018 (GLOBE NEWSWIRE) --  InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD Logo.png
InspireMD Announces First Patient Treated with CGuard™ EPS in India 
March 05, 2018 08:07 ET | InspireMD, Inc.
Patient with severe stenosis, calcification and thrombosis successfully treated with CGuard™ EPS TEL AVIV, ISRAEL, March 05, 2018 (GLOBE NEWSWIRE) --  InspireMD, Inc. (NYSE AMER:NSPR), a leader...